#LifeForward
#NEWS: Phase III trial data for people living with #obesity, overweight & #T2D were presented today at @easdnews.bsky.social

These results will help us understand how survodutide can provide weight loss benefits whilst improving blood sugar levels.

👉 go.boehringer.com/SBqTr

#LifeForward #EASD2026
October 1, 2026 at 7:36 AM
#NEWS: The @ec.europa.eu has granted marketing authorization for our treatment of adults with idiopathic pulmonary fibrosis (IPF) and adults with progressive pulmonary fibrosis (PPF).

Learn more: www.boehringer-ingelheim.com/human-health...

#LifeForward #PulmonaryFibrosis
July 17, 2026 at 6:30 AM
#NEWS: Phase II trial initiated for our investigational triple receptor agonist for #obesity.

This trial will help drive understanding of both biological and behavioural drivers of obesity to improve health outcomes.

Read more 👉 go.boehringer.com/oxr1a

#LifeForward
July 16, 2026 at 6:47 AM
#NEWS: Full data from two Phase III trials in people living with #obesity presented at #ADA2026.

These results show potential to address patients’ unmet needs in obesity and liver health.

Read more 👉 go.boehringer.com/4hch

#LifeForward #ADASciSessions
June 7, 2026 at 6:40 PM
Lung cancers are not all the same. For some, a HER2 (ERBB2) gene mutation is what is driving it.

Biomarker testing identifies what’s behind each person’s cancer, giving care teams critical information to help inform clinical decisions. Learn more: bit.ly/4nUyHXq

#LifeForward #Oncology #LungCancer
May 30, 2026 at 9:36 AM
#NEWS: The CHMP of @ema.europa.eu has issued a positive opinion for our medicine in #IPF and #PPF – a major milestone in the EU review process and a step forward for people living with these serious lung diseases.

Learn more: go.boehringer.com/XxUd

#LifeForward #PulmonaryFibrosis
May 22, 2026 at 1:05 PM
#NEWS: Our targeted therapy has received approval in China as a first-line treatment for adults with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), making it an initial therapy option.

🧪Learn more: go.boehringer.com/_xdMW

#LifeForward #Oncology #LungCancer
May 22, 2026 at 7:41 AM
#NEWS: New data in NSCLC, SCLC and extrapulmonary neuroendocrine carcinoma will be presented at #ASCO26, adding to our growing body of research on targeted approaches in difficult-to-treat cancers.

Learn more: go.boehringer.com/UfRlZ

#LifeForward #Oncology
May 21, 2026 at 9:00 PM
#NEWS: Together with Eko Health Inc., we’re launching an AI based solution to detect, visualize and grade heart murmurs in dogs. Eko Vet+™ | CANINEBEAT® AI supports veterinarians in identifying murmurs that may otherwise go unnoticed.

Learn more: go.boehringer.com/6EMA5

#VetTech #LifeForward
April 29, 2026 at 10:45 AM
#NEWS: Our Phase III trial in people living with #obesity or overweight without type 2 diabetes has met its co-primary endpoints. Obesity is linked to liver disease, type 2 diabetes and cardiovascular disease.

Read more 👉 go.boehringer.com/Nsw9

#LifeForward
April 28, 2026 at 6:12 AM
#NEWS: We’re launching a new vaccine to help prevent mastitis, one of the most common diseases in dairy cows. Designed for a two-dose administration, it offers early and long‑lasting protection.
Learn more here: go.boehringer.com/m8oFO
#LifeForward
April 13, 2026 at 10:01 AM
Rabies is fatal once symptoms appear – but it’s preventable. Supported by our Stop Rabies program, Ecuador is accelerating efforts to eliminate dog‑mediated rabies by 2030 through vaccination, education and stronger surveillance.
Read more 🧪👉 go.boehringer.com/HlQ7Y

#OneHealthSummit #LifeForward
April 9, 2026 at 8:09 AM
#NEWS: Today, the @fda.gov approved our orally administered therapy for patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC) as an initial treatment. This marks the first approved targeted therapy for this use.

Learn more: go.boehringer.com/VHCH-

#LifeForward
February 26, 2026 at 6:46 PM
#NEWS: New Phase II trial results in primary focal segmental glomerulosclerosis (FSGS) published in The Lancet.

Primary FSGS is a rare, progressive kidney disease, which can end in kidney failure.

Read more 👉 go.boehringer.com/VecpO
#LifeForward
January 28, 2026 at 6:38 AM
#NEWS: The @fda.gov has approved our new treatment for progressive pulmonary fibrosis (PPF) in adults. The approval provides hope to people living with this life-threatening condition.

Learn more here: go.boehringer.com/SYRTX

#LifeForward #PulmonaryFibrosis
December 19, 2025 at 5:30 PM
#NEWS: China’s National Medical Products Administration (NMPA) has approved our new treatment for progressive #PulmonaryFibrosis (PPF). 🧪

In a field where milestones are scarce, today signals meaningful momentum for the PPF community.

Learn more: go.boehringer.com/ao0kp

#LifeForward
December 10, 2025 at 10:58 AM
#NEWS: Our investigational targeted therapy has been awarded a Commissioner’s National Priority Voucher from the U.S. FDA.

Find out more here go.boehringer.com/Fyr8N

#LifeForward #Oncology
November 10, 2025 at 1:55 PM
The immune system has the remarkable ability to identify and eliminate cancer cells.

Our oncology research includes the investigation of T-cell engagers, focusing on leveraging immune mechanisms in cancer therapy.

Learn more 🧪: go.boehringer.com/Ki82v

#LifeForward #Oncology
October 20, 2025 at 7:57 AM
#NEWS: Our latest oncology research in HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC) has been presented at #ESMO25.

These advancements have the potential to fulfill patients’ unmet needs.

🧪 Find out more: go.boehringer.com/FU9K9

#LifeForward #Oncology
October 17, 2025 at 2:05 PM
Living with cancer, the small, positive moments often have the biggest impact.

We're here to celebrate these 'Big Little Things': small victories, time with loved ones, and everyday joys.

🧪 Discover how these moments make a difference: go.boehringer.com/YomJY

#LifeForward #Oncology
October 16, 2025 at 9:48 AM
#NEWS: Ten of our oncology abstracts will be presented at #ESMO25, sharing our ongoing research efforts in hard-to-treat cancers.

🧪 Learn more: go.boehringer.com/GCZ1

#LifeForward #Oncology
October 10, 2025 at 2:48 PM
#NEWS:  The U.S. Food and Drug Administration (FDA) has approved the first new treatment for idiopathic pulmonary fibrosis (#IPF) in over a decade. 🧪

Learn more here: go.boehringer.com/rtx-w

#LifeForward
October 9, 2025 at 10:02 AM
#NEWS: New pooled phase III data in idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) presented at the European Respiratory Society (ERS) Congress 2025: go.boehringer.com/rdYYD 🧪

 #ERS2025 #LifeForward
September 29, 2025 at 6:46 AM
#NEWS for media: Our targeted cancer therapy has received approval in China for use in previously treated people with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC). 🧪

Learn more here: go.boehringer.com/YrIQ

#LifeForward #Oncology
September 1, 2025 at 9:04 AM
At 37, Samantha was diagnosed with non-small cell #lungcancer (NSCLC).

With support from her husband Justin and care team, she learned about #biomarker testing 🧪 to understand her cancer’s unique profile.

#LifeForward #Oncology #Medsky
August 15, 2025 at 2:24 PM